Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | LCK | P06239 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | BCL9 | O00512 | 1/20 | 0.46 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6949116 | 0.88 | SMN1; SMN2 (0.51) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL22869197 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2D6 | |
| SCHEMBL8696423 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2D6 | |
| SCHEMBL2356129 | 0.86 | SMN1; SMN2 (0.62) | SMN1; SMN2NPC1RAB9ACYP2C19CYP3A4 | |
| SCHEMBL11088727 | 0.85 | ALDH1A1 (0.45) | SMN1; SMN2ALDH1A1HTTL3MBTL1CHRM1 | |
| SCHEMBL1843641 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2D6 | |
| SCHEMBL30922511 | 0.84 | ACKR3 (0.52) | HTTMEN1KMT2AJAK2JAK1 | |
| SCHEMBL25597563 | 0.84 | ACKR3 (0.52) | HTTMEN1KMT2AJAK2JAK1 | |
| SCHEMBL31739454 | 0.84 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1RAB9ACYP2C19ALDH1A1 | |
| SCHEMBL3443919 | 0.84 | SMN1; SMN2 (0.53) | SMN1; SMN2NPC1RAB9ACYP2C19CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | SANOFI-AVENTIS (FR) | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036469-A1 | 2,6-SUBSTITUTED-4-MONOSUBSTITUTED AMINO-PYRIMIDINE AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS | PTGDR2, PTGDR, PTGER2 | SMN1; SMN2 1857/4885NPC1 1522/4885RAB9A 3720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.